XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and License Agreements - Additional Information (Details) - USD ($)
shares in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jan. 31, 2022
Dec. 31, 2021
Jun. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Current portion of deferred revenue $ 159,902,000   $ 86,270,000   $ 159,902,000   $ 159,902,000  
Long-term portion of deferred revenue $ 198,288,000   $ 262,303,000   198,288,000   $ 198,288,000  
Orbital                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Collaboration arrangement, initial term 3 years              
Collaboration arrangement extension term description             which may be extended for up to two successive one-year periods  
Collaboration agreement performance obligation revenue recognized         0   $ 0  
Collaboration agreement aggregate transaction price $ 25,500,000       25,500,000   $ 25,500,000  
Collaboration agreement performance obligation revenue period for recognition             3 years  
Deferred revenue 25,500,000       25,500,000   $ 25,500,000  
Current portion of deferred revenue 8,500,000       8,500,000   8,500,000  
Long-term portion of deferred revenue 17,000,000.0       17,000,000.0   $ 17,000,000.0  
Apellis Pharmaceuticals, Inc                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Agreement description             In June 2021, the Company entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of certain of the Company’s base editing technology to discover new treatments for complement system-driven diseases. Under the terms of the Apellis Agreement, the Company will conduct preclinical research on up to six base editing programs that target specific genes within the complement system in various organs, including the eye, liver, and brain. Apellis has an exclusive option to license any or all of the six programs, or in each case, an Opt-In Right, and will assume responsibility for subsequent development. The Company may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program instead of a license. The collaboration is managed on an overall basis by an alliance steering committee formed by an equal number of representatives from the Company and Apellis.  
Collaboration arrangement, initial term       5 years        
Upfront revenue recognized             $ 0  
Collaboration agreement performance obligation revenue recognized         3,000,000.0 $ 800,000 7,500,000 $ 800,000
Collaboration agreement aggregate transaction price       $ 75,000,000.0        
Upfront fee receivable upon signing contract       50,000,000.0        
Collaboration agreement first anniversary amount receivable       $ 25,000,000.0        
Collaboration agreement first anniversary payment received             25,000,000.0  
Current portion of deferred revenue 27,800,000       27,800,000   27,800,000  
Long-term portion of deferred revenue 37,900,000       37,900,000   $ 37,900,000  
Apellis Pharmaceuticals, Inc | Maximum                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Collaboration arrangement extension term       2 years        
Pfizer                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Agreement description             In December 2021, the Company entered into a research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on the use of certain of the Company’s base editing technology to develop in vivo therapies for rare genetic diseases of the liver, muscle, and central nervous system. Under the terms of the Pfizer Agreement, the Company will conduct all research activities through development candidate selection for three base editing programs that target specific genes corresponding to specific diseases that are the subject of such programs. Pfizer will have exclusive rights to license each of the three programs at no additional cost, each an Opt-In Right, and will assume responsibility for subsequent development and commercialization. At the end of the Phase 1/2 clinical trials, the Company may elect to enter into a global co-development and co-commercialization agreement with Pfizer with respect to one program licensed under the collaboration for an option exercise fee equal to a percentage of the applicable development costs incurred by Pfizer, or the Participation Election. In the event the Company elects to exercise its Participation Election, upon the payment of its option exercise fee, Pfizer and the Company would share net profits as well as development and commercialization costs in a 65%/35% (Pfizer/Company) split for such program. The research collaboration is managed on an overall basis by a Joint Research Committee, or JRC, formed by an equal number of representatives from the Company and Pfizer.  
Collaboration arrangement, initial term     4 years          
Collaboration arrangement extension term description             extended for an additional year on a program-by-program basis  
Potential total consideration     $ 1,350,000,000          
Nonrefundable upfront payment receivable     300,000,000.0          
Collaboration agreement upfront payment received   $ 300,000,000.0            
Collaboration agreement performance obligation revenue recognized         12,800,000 $ 0 $ 33,400,000 $ 0
Collaboration agreement aggregate transaction price     $ 300,000,000.0          
Earn-out payment period     10 years          
Current portion of deferred revenue 123,600,000       123,600,000   123,600,000  
Long-term portion of deferred revenue $ 143,000,000.0       $ 143,000,000.0   $ 143,000,000.0  
Pfizer | Assigned to Company | Upon Participation Election                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Net profits as well as development and commercialization costs percentage     35.00%          
Pfizer | Assigned to Pfizer | Upon Participation Election                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Net profits as well as development and commercialization costs percentage     65.00%          
Pfizer | Maximum | Per Program                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Development regulatory and commercial milestones receivable     $ 350,000,000.0          
Orbital                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Common stock shares received at closing 75       75   75  
Percentage of fully diluted equity interest 31.50%       31.50%   31.50%